大麻醇通过调节三胺催化剂抑制了转移性割抵抗性前列腺癌的进展和复发
Ethar A Mudhish1, Hassan Y Ebrahim1, Iman E Helal1,2
1School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, Louisiana 71201, United States.
ACS pharmacology & translational science
|December 19, 2024
概括
(-) - - 大麻二醇 (CBD) 在转移性割抵抗性前列腺癌 (mCRPC) 中有效向IDO1-Kyn-AhR通路. 这种非精神活性化合物在临床前模型中抑制了瘤的进展和复发.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 是一种侵袭性疾病.
- 氨酸2,3-二氧化酶-1 (IDO1) - 氨酸 (Kyn) - 烯酸碳化合物受体 (AhR) 轴在mCRPC中失调,促进瘤发生.
- (-) - - 大麻素 (CBD) 是一种非精神活性植物性大麻素,具有已证明的抗瘤作用.
研究的目的:
- 研究CBD作为mCRPC治疗剂的潜力.
- 为了确定CBD对前列腺癌中IDO1-Kyn-AhR通路的影响.
- 在mCRPC的临床前模型中评估CBD的疗效.
主要方法:
- 在体外研究中评估了CBD对前列腺癌细胞活力,克隆性和IDO1和AhR的表达的影响.
- 在体内研究中,在裸体小鼠中使用了mCRPC的异种移植模型,口服服CBD.
- 监测了瘤进展,手术切除后复发以及全身Kyn水平.
主要成果:
- 在实验室中,CBD表现出强大的,剂量依赖的前列腺癌细胞活力和克隆性抑制作用.
- CBD治疗减少了前列腺癌细胞中的IDO1和AhR表达.
- 口服CBD给药抑制了mCRPC异种移植的进展和复发,并显著降低了小鼠的全身Kyn水平.
结论:
- 在前列腺癌中,CBD有效地准IDO1-Kyn-AhR轴.
- CBD在控制mCRPC进展和复发方面表现出显著的临床前疗效.
- 通过调节二的代谢,CBD代表了对mCRPC的有希望的非精神活性植物性大麻素治疗.
相关概念视频
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
201
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
201
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K